It's hard to beat the power of dividend-paying stocks. They have outperformed non-payers significantly. If you don't have many dividend-paying stocks in your portfolio, you might want to rethink your asset allocation because dividend payers can be surprisingly powerful long-term performers. For starters, a company generally needs to grow enough to have relatively reliable income, giving management the confidence with which to initiate -- and then maintain -- a dividend payment to shareholders. Such companie ...

Since I last checked on pharmaceutical company AbbVie Inc. (NYSE: ABBV ) in August, its share price hasn't gone anywhere. But the release of its third quarter (Q3 2024) results shows investors are happy Manika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the green economy. Her investing group, Green Growth Giants , takes th ...

Financial Data and Key Metrics - AbbVie reported Q3 2024 sales of $14.5 billion, reflecting robust operational growth of 4.9% [55] - The ex-Humira platform grew nearly 18%, contributing significantly to the overall performance [55] - Adjusted EPS for Q3 was $3, $0.10 above the guidance midpoint, with a full-year adjusted EPS guidance raised to $10.90-$10.94 [55][57] - Skyrizi and Rinvoq combined sales are expected to exceed $17 billion in 2024, $1.3 billion above initial expectations [8] Business Line Performance - Immunology revenues were $7 billion, with Skyrizi sales up 51.5% to $3.2 billion and Rinvoq sales up 47.4% to $1.6 billion [14][18] - Oncology revenues were $1.7 billion, with Venclexta sales up 18.2% to $677 million [24] - Neuroscience revenues grew 16% to $2.3 billion, driven by Vraylar sales up 16.6% to $875 million [26] - Aesthetics sales grew 1.8% to $1.2 billion, with Botox Cosmetic sales up 6.5% to $414 million [31] Market Performance - Skyrizi achieved in-play biologic share leadership in approximately 30 key countries, with a 32% U.S. in-play patient share in Crohn's disease [16] - Rinvoq captured double-digit in-play patient share in the U.S. for ulcerative colitis and Crohn's disease, with both indications available in over 75 countries [18] - Venclexta saw strong momentum in Europe due to guideline changes recommending its combination use with BTK inhibitors [24] Strategic Direction and Industry Competition - AbbVie completed the acquisition of Cerevel Therapeutics, strengthening its neuroscience pipeline, particularly in Parkinson's and schizophrenia [10] - The company is advancing key R&D programs, including the U.S. approval of Vyalev for advanced Parkinson's and the submission of Teliso-V for non-small cell lung cancer [11] - Skyrizi and Rinvoq have demonstrated strong differentiation with compelling head-to-head data against competitors like Humira, Stelara, and Dupixent [21] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in achieving robust mid-single-digit growth for 2025, driven by strong performance from Skyrizi and Rinvoq [72] - The company highlighted the potential for long-term growth in immunology, oncology, neuroscience, and aesthetics, supported by a strong pipeline and strategic acquisitions [7][10] - AbbVie announced a 5.8% increase in its quarterly cash dividend, reflecting confidence in its financial stability and growth prospects [12] Other Important Information - AbbVie raised its full-year revenue guidance by $500 million, now expecting total revenues of approximately $56 billion [57] - The company generated $11 billion in free cash flow, supporting a strong dividend and debt repayment strategy [64] - AbbVie is on track to achieve a net leverage ratio of two times by the end of 2026 [65] Q&A Session Summary Question: Humira Volume Shifting to Newer Drugs and 2025 Growth Outlook - Management confirmed that the shift of Humira volumes to Skyrizi and Rinvoq is a net positive, with robust mid-single-digit growth expected for 2025 [72][73] - The company noted that consensus estimates for Humira may need adjustment due to faster-than-expected erosion [73] Question: Skyrizi Head-to-Head Trial Against Entyvio - AbbVie is confident in Skyrizi's superiority in ulcerative colitis, particularly in naive patients, with endoscopic improvement rates of 76% [82][83] Question: Emraclidine Data Expectations - Management expects emraclidine to differentiate based on its safety profile and tolerability, with data readouts expected in Q4 2024 [87][88] Question: Skyrizi and Rinvoq Formulary Positioning for 2025 - AbbVie anticipates no material changes in formulary access for Skyrizi and Rinvoq in 2025, with low single-digit rebate changes expected [95][96] Question: Aesthetics Business Long-Term Outlook - The company remains confident in achieving $9 billion in aesthetics sales by 2029, driven by innovation like BoNT/E, despite near-term economic challenges [111][112] Question: Eye Care and Future Therapeutic Areas - Eye care is part of AbbVie's five key growth areas, with potential for opportunistic investments in metabolics and cardio if differentiation is achieved [116][117] Question: Emraclidine Placebo Effect Management - AbbVie has implemented strategies to manage placebo effects in emraclidine trials, including limiting sites and rigorous rater training [121][122] Question: Aliada Acquisition and Neuroscience Strategy - The Aliada acquisition enhances AbbVie's neuroscience pipeline, particularly in Alzheimer's, with potential for subcutaneous dosing and reduced ARIA risk [125][126] Question: Vraylar Channel Mix Pressure - Vraylar experienced slight channel mix pressure in Q3, leading to a $100 million reduction in guidance, offset by growth in Botox Therapeutics [143][144]

AbbVie Inc. (ABBV) reported adjusted earnings of $3.00 per share for the third quarter of 2024, beating the Zacks Consensus Estimate of $2.92. The reported earnings also exceeded the company's guidance of $2.88-$2.92 issued earlier this month. Earnings increased 1.7% year over year. ABBV's revenues of $14.46 billion also beat the Zacks Consensus Estimate of $14.28 billion. Sales rose 3.8% year over year on a reported basis and 4.9% on an operational basis. Revenues in third quarter were driven by robust sal ...

For the quarter ended September 2024, AbbVie (ABBV) reported revenue of $14.46 billion, up 3.8% over the same period last year. EPS came in at $3.00, compared to $2.95 in the year-ago quarter.The reported revenue represents a surprise of +1.29% over the Zacks Consensus Estimate of $14.28 billion. With the consensus EPS estimate being $2.92, the EPS surprise was +2.74%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their ...

AbbVie (ABBV) came out with quarterly earnings of $3 per share, beating the Zacks Consensus Estimate of $2.92 per share. This compares to earnings of $2.95 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 2.74%. A quarter ago, it was expected that this drugmaker would post earnings of $2.57 per share when it actually produced earnings of $2.65, delivering a surprise of 3.11%. Over the last four quarters, the company has surpass ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2024 ABBVIE INC. (Exact name of registrant as specified in its charter) Delaware 001-35565 (State or other Jurisdiction (Commission File Number) of Incorporation) _____________________________________________________ 1 North Wauke ...

Reports Third-Quarter Diluted EPS of $0.88 on a GAAP Basis, a Decrease of 12.0 Percent; Adjusted Diluted EPS of $3.00, an Increase of 1.7 Percent; These Results Include an Unfavorable Impact of $0.04 Per Share Related to Acquired IPR&D and Milestones Expense  Delivers Third-Quarter Net Revenues of $14.460 Billion, an Increase of 3.8 Percent on a Reported Basis or 4.9 Percent on an Operational Basis  Third-Quarter Global Net Revenues from the Immunology Portfolio Were $7.046 Billion, an Increase of 3.9 Per ...

These 3 dividend growth stocks have crushed the market and show no signs of slowing down.The power of dividend growth investing lies in one simple truth: Companies that consistently raise their dividends have historically outperformed the broader market since 1900. These elite businesses combine robust revenue growth, strong fundamentals, and shareholder-friendly management teams.The greatest dividend growth stories share common traits: durable competitive advantages, reasonable payout ratios, and proven re ...

AbbVie Inc ABBV will be reporting its third-quarter earnings on Wednesday. Wall Street expects $2.92 in EPS and $14.28 billion in revenues as the company reports before market hours. Ahead of its third-quarter earnings report, AbbVie bolstered its Alzheimer's research efforts with the $1.4 billion acquisition of Aliada Therapeutics, announced on Monday. Aliada brings an innovative approach to delivering treatments directly to the brain, with its lead drug candidate, ALIA-1758, showing promise for Alzheimer' ...